pancreatic cancer

Financial analysts seemed convinced of the long-term advantages of the deal but noted that investors may remain skeptical in the near term.

Exact Sciences and the Mayo Clinic are working to develop a blood test for pancreatic cancer that might be able to diagnose patients with early-stage disease.

The firm recently submitted an application to the US Food and Drug Administration to expand Cologuard's label to the 45 to 49 age group.

For the Evry, France-based company, the grant will support its vision of making its technology available as a platform for running oncology assays.

Researchers combined a new and established biomarker to detect nearly 70 percent of pancreatic cancers with a less than 5 percent false-positive rate.